These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Impact of radiotherapy on the immune landscape in oesophageal adenocarcinoma. Donlon NE; Davern M; O'Connell F; Sheppard A; Heeran A; Bhardwaj A; Butler C; Narayanasamy R; Donohoe C; Phelan JJ; Lynam-Lennon N; Dunne MR; Maher S; O'Sullivan J; Reynolds JV; Lysaght J World J Gastroenterol; 2022 Jun; 28(21):2302-2319. PubMed ID: 35800186 [TBL] [Abstract][Full Text] [Related]
9. Chemotherapy regimens induce inhibitory immune checkpoint protein expression on stem-like and senescent-like oesophageal adenocarcinoma cells. Davern M; Donlon NE; Sheppard A; Connell FO; Hayes C; Bhardwaj A; Foley E; Toole DO; Lynam-Lennon N; Ravi N; Reynolds JV; Maher SG; Lysaght J Transl Oncol; 2021 Jun; 14(6):101062. PubMed ID: 33765543 [TBL] [Abstract][Full Text] [Related]
10. Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy. Yanik EL; Kaunitz GJ; Cottrell TR; Succaria F; McMiller TL; Ascierto ML; Esandrio J; Xu H; Ogurtsova A; Cornish T; Lipson EJ; Topalian SL; Engels EA; Taube JM JAMA Oncol; 2017 Jul; 3(7):974-978. PubMed ID: 28334399 [TBL] [Abstract][Full Text] [Related]
11. Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer. Dehno MN; Li Y; Weiher H; Schmidt-Wolf IGH Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349280 [TBL] [Abstract][Full Text] [Related]
12. Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands. Garman B; Jiang C; Daouti S; Kumar S; Mehta P; Jacques MK; Menard L; Manjarrez-Orduno N; Dolfi S; Mukherjee P; Rai SC; Lako A; Koenitzer JD; David JM Front Immunol; 2023; 14():1151748. PubMed ID: 37795090 [TBL] [Abstract][Full Text] [Related]
13. Improving the synergistic combination of programmed death-1/programmed death ligand-1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment. Mudassar F; Shen H; Cook KM; Hau E J Med Imaging Radiat Oncol; 2022 Jun; 66(4):560-574. PubMed ID: 35466515 [TBL] [Abstract][Full Text] [Related]
14. HUVECs affect HuT-78 cell apoptosis and cytokine production via the HIF-1α-PD-L1/PD-1 pathway under hypoxia. Qiang L; Hong L; Jian X; Zhanlin Z Int Immunopharmacol; 2023 May; 118():110010. PubMed ID: 36924563 [TBL] [Abstract][Full Text] [Related]
15. Immune checkpoints in the tumor microenvironment. Toor SM; Sasidharan Nair V; Decock J; Elkord E Semin Cancer Biol; 2020 Oct; 65():1-12. PubMed ID: 31265893 [TBL] [Abstract][Full Text] [Related]
16. GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer. Huntington KE; Louie AD; Srinivasan PR; Schorl C; Lu S; Silverberg D; Newhouse D; Wu Z; Zhou L; Borden BA; Giles FJ; Dooner M; Carneiro BA; El-Deiry WS Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446056 [TBL] [Abstract][Full Text] [Related]
17. Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC. Della Corte CM; Ciaramella V; Ramkumar K; Vicidomini G; Fiorelli A; Nardone V; Cappabianca S; Cozzolino I; Zito Marino F; Di Guida G; Wang Q; Cardnell R; Gay CM; Ciardiello D; Martinelli E; Troiani T; Martini G; Napolitano S; Wang J; Byers LA; Ciardiello F; Morgillo F J Transl Med; 2022 Nov; 20(1):541. PubMed ID: 36419183 [TBL] [Abstract][Full Text] [Related]
18. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094 [No Abstract] [Full Text] [Related]
19. The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer. Liu L; Lim MA; Jung SN; Oh C; Won HR; Jin YL; Piao Y; Kim HJ; Chang JW; Koo BS Phytomedicine; 2021 Nov; 92():153758. PubMed ID: 34592487 [TBL] [Abstract][Full Text] [Related]
20. Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model. Zhang H; Xie W; Zhang Y; Dong X; Liu C; Yi J; Zhang S; Wen C; Zheng L; Wang H Cancer Gene Ther; 2022 May; 29(5):456-465. PubMed ID: 34561555 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]